

Live Programme 07/05/2021

**PROGRAMME OF LIVE SESSIONS: CEST timing**

The programme below will take place live. This time schedule corresponds to **CEST timing**. [Click here: https://www.calculator.net/time-zone-calculator.html](https://www.calculator.net/time-zone-calculator.html) to adapt the CET time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



**E-Conference: How I Manage CAR-T Therapies and Bispecific Antibodies for My Patients  
September 6-9, 2021 - #ESHCART2021**

**Chairpersons: Peter Borchmann (Cologne), Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)**

**Monday, September 6, 2021**

14:40-14:45 **Welcome: Peter Borchmann, Ulrich Jäger, Marie José Kersten**

**SESSION I – Diffuse large B-cell Lymphoma: How to optimize the benefit of CAR T-cell therapy?**

**Chairs: Gilles Salles (New York) and Marie José Kersten (Amsterdam)**

- |             |  |   |
|-------------|--|---|
| 14:45-14:50 | Introduction   | Gilles Salles (New York) and Marie José Kersten (Amsterdam) |
| 14:50-15:10 | Case-based lecture:<br>Real world data: patient selection and bridging strategies? | Catherine Thieblemont (Paris)                               |
| 15:10-15:20 | Interactive case:<br>Monitoring CAR expansion and persistence?                     | Peter Borchmann (Cologne)                                   |
| 15:20-15:40 | Perspectives:<br>Ongoing clinical trials and developments in DLBCL                 | Gilles Salles (New York)                                    |
| 15:40-16:00 | Case-based lecture:<br>Biology of CAR therapy and mechanisms of resistance         | Robbie Majzner (Stanford)                                   |
| 16:00-16:05 | <i>Selected brief oral communication</i>   |   |
| 16:05-16:35 | Panel discussion   |   |

16:35-16:45 **Coffee Break**

**SESSION II – Diffuse large B-cell lymphoma: How to minimize potential risks of CAR T-cell therapy?**

**Chairs: Peter Borchmann (Cologne), Stephan Grupp (Philadelphia)**

16:45-16:50	Introduction	Peter Borchmann (Cologne), Stephan Grupp (Philadelphia)
16:50-17:00	Interactive case: CRS grading and management	Marion Subklewe (Munich)
17:00-17:10	Interactive case: ICANS grading and management	Peter Schellongowski (Vienna)
17:10-17:30	Case-based lecture: Novel strategies to prevent/treat CRS/ICANS	Stephan Grupp (Philadelphia)
17:30-17:50	Case-based lecture: Hypogammaglobulinaemia and late and persisting cytopaenias	Ulrich Jäger (Vienna)
17:50-18:10	Perspectives: Learning from doing?	Christian Chabannon (Marseille)
18:10-18:15	<i>Selected brief oral communication</i>	
18:15-18:45	Panel discussion	
18:55-19:55	<b>Slot for a satellite symposium (already booked)</b>	

**Tuesday, September 7, 2021**

**12:20-13:20 Slot for a satellite symposium (already booked)**

**13:30-14:30 Slot for a satellite symposium (already booked)**

**SESSION III – Multiple Myeloma: targeting BCMA with bispecifics and CARs**

**Chairs: Hermann Einsele (Würzburg), Maria Victoria Mateos (Salamanca)**

14:40-14:45	Introduction	Hermann Einsele (Würzburg), Maria Victoria Mateos (Salamanca)
14:45-14:55	Interactive case: Multiple Myeloma	Maria Victoria Mateos (Salamanca)
14:55-15:15	Case-based lecture: BCMAxCD3 for multiple r/r MM	Max Topp (Würzburg)
15:15-15:35	Case-based lecture: BCMA targeted CAR T-cell therapy for multiple r/r MM	Sham Mailankody (New York)
15:35-15:55	Perspectives: Developments beyond targeting BCMA	Michael Hudecek (Würzburg)
15:55-16:05	Interactive case: Multiple Myeloma	Maria Victoria Mateos (Salamanca)
16:05-16:10	<i>Selected brief oral communication</i>	
16:10-16:40	Panel discussion	
16:40-16:50	<b>Coffee break</b>	

16:50-17:45 **DEBATE 1 – The future of myeloma therapy: how can T-cell engagement be integrated into current treatment strategies?**

**Chair:** Maria Victoria Mateos (Salamanca)

16:50-16:55 Introduction Maria Victoria Mateos (Salamanca)

Audience votes

16:55-17:10 Bispecific antibodies Hermann Einsele (Würzburg)

17:10-17:25 CARs Sham Mailankody (New York)

Audience votes again

17:25-17:45 Discussion

17:45-18:35 **ROUNDTABLE 1 – Affordability of and access to CAR T-cell and bispecifics treatment**

**Chair:** Ulrich Jäger (Vienna)

**Discussants:** Carin Uyl-de Groot (Rotterdam), Ananda Plate (Munich), Bertram Glass (Berlin), Ana Hidalgo-Simon (Amsterdam), Emanuele Ostuni (Basel)

18:35-18:50 **FLASH TALKS**

18:35-18:40 Neuroblastoma

Franco Locatelli (Rome)

18:40-18:45 CAR T-cells for solid childhood tumours

Concetta Quintarelli (Rome)\*

18:45-18:50 Driving CARs to last

Speaker TBA\*

*To learn more and get answers to all your questions, make sure you pre-register to join the live Meet the Expert session of your choice.*

18:50-19:50 **Simultaneous Meet the Expert Sessions:**

1. Neuroblastoma

Franco Locatelli (Rome)

2. CAR T-cells for solid childhood tumours

Concetta Quintarelli (Rome)\*

3. Driving CARs to last

Speaker TBA\*

**Wednesday, September 8, 2021**

**13:30-14:30 Slot for a satellite symposium**

**SESSION IV – Bispecific antibodies in the treatment of B-NHL**

**Chairs:** Martin Hutchings (Copenhagen), Ulrich Jäger (Vienna)

14:40-14:45 Introduction Martin Hutchings (Copenhagen), Ulrich Jäger (Vienna)

14:45-14:55 Interactive case Marion Subklewe (Munich)

14:55-15:15 Case-based lecture: Bispecifics in relapsed DLBCL? Stephan Schuster (Philadelphia)

15:15-15:35 Case-based lecture: Bispecifics in first line DLBCL? Richard Greil (Salzburg)

15:35-15:55 Case-based lecture: other lymphomas Martin Hutchings (Copenhagen)

15:55-16:00 *Selected brief oral communication*

16:00-16:30 Panel discussion

16:30-16:40 **Coffee break**

16:40-17:35 **DEBATE 2 – Future 2<sup>nd</sup> and 3<sup>rd</sup> line treatment of r/r aggressive B-cell NHL: auto and allo-transplant, bispecifics, or CARs?**

**Chair: John Gribben (London)**

16:40-16:45 Introduction

John Gribben (London)

Audience votes

16:45-16:55 Allo-transplant

Bertram Glass (Berlin)

16:55-17:05 Bispecific antibodies

Martin Hutchings (Copenhagen)

17:05-17:15 CAR T-cells

Marie José Kersten (Amsterdam)

Audience votes again

17:15-17:35 Discussion

17:35-18:20 **ROUNDTABLE 2 – CARs in solid tumours**

**Chair: Michael Hudecek (Würzburg)**

17:35-17:40 Introduction

Michael Hudecek (Würzburg)

17:40-17:50 GD2-targeting CAR T-cells in childhood tumours

Franco Locatelli (Rome)

17:50-18:00 CAR T-cells for treatment of atypical teratoid/rhabdoid tumours

Concetta Quintarelli (Rome)\*

18:00-18:10 Driving CARs to last

Speaker TBA\*

18:10-18:20 Discussion

18:20-18:40 **FLASH TALKS**

18:20-18:25 NK cell CARs

Ulrike Köhl (Leipzig)

18:25-18:30 Bispecific CAR T-cells

Peter Borchmann (Cologne)

18:30-18:35 Sleeping Beauty

Michael Hudecek (Würzburg)

18:35-18:40 Point of care production of CAR T-cells

Alvaro Urbano-Ispizua (Barcelona)

*To learn more and get answers to all your questions, make sure you pre-register to join the live Meet the Expert session of your choice.*

18:50-19:50 **Simultaneous Meet the Expert Sessions:**

1. NK cell CARs

Ulrike Köhl (Leipzig)

2. Bispecific CAR T-cells

Peter Borchmann (Cologne)

3. Sleeping Beauty

Michael Hudecek (Würzburg)

4. Point of care production of CAR T-cells

Alvaro Urbano-Ispizua (Barcelona)

12:00-13:00 Mentored poster walk

13:10-14:10 Slot for a satellite symposium

**SESSION V – Acute lymphoblastic leukaemia (ALL): the role of CARs and Bispecifics - lessons from paediatric haematology**

**Chairs:** Peter Bader (Frankfurt), Jochen Büchner (Oslo)

14:20-14:25	Introduction	Peter Bader (Frankfurt), Jochen Büchner (Oslo)
14:25-14:35	Interactive case topic 1	Jochen Büchner (Oslo)
14:35-14:55	Case-based lecture: CAR T-cell therapy in childhood ALL: what can we learn for adult patients?	Peter Bader (Frankfurt)
14:55-15:15	Case-based lecture: CAR-T after allogeneic transplant	André Baruchel (Paris)
15:15-15:35	Case-based lecture: CAR-T for bridging to allogeneic transplant or repeated CARs?	Sara Ghorashian (London)
15:35-15:45	Interactive case topic 2	Jochen Büchner (Oslo)
15:45-15:50	<i>Selected brief oral communication</i>	
15:50-16:20	Panel discussion	
16:20-16:30	<b>Coffee break</b>	

**SESSION VI – Perspectives: CARs and bispecifics for haematological malignancies**

**Chairs:** Cameron Turtle (Seattle), Marion Subklewe (Munich)

16:30-16:35	Introduction	Cameron Turtle (Seattle), Marion Subklewe (Munich)
16:35-16:55	Perspectives: Mantle Cell Lymphoma and Follicular Lymphoma	Marie José Kersten (Amsterdam)
16:55-17:15	Perspectives: T-cell Non-Hodgkin's Lymphoma	Claire Roddie (London)
17:15-17:35	Perspectives: Acute Myeloid Leukaemia	Chiara Bonini (Milan)
17:35-17:55	Perspectives: Chronic Lymphocytic Leukaemia	Cameron Turtle (Seattle)
17:55-18:00	<i>Selected brief oral communication</i>	
18:00-18:30	Panel discussion	
18:30-19:00	<b>Keynote lecture</b> <b>Chairs: Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)</b>	
18:30-18:35	Introduction	Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam)
18:35-18:55	The role of CAR T-cell therapy in cancer in 2030	Carl June (Philadelphia)

18:55-19:00 Discussion

19:00-19:05 **Closing remarks: Peter Borchmann, Ulrich Jäger, Marie José Kersten**

## **MEETING CLOSURE**

*\* Speaker to be confirmed*